BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Xenomics Inc. (XNOM) Executes Research Contract With North Shore-LIJ Health Sys. To Begin Human Clinical Studies Of Non-Invasive Prenatal DNA Tests


10/19/2005 5:10:23 PM

NEW YORK--(BUSINESS WIRE)--May 9, 2005--Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, has executed a contract with North Shore-Long Island Jewish (LIJ) Health System, one of the nation's largest healthcare institutions, to begin conducting human clinical studies in the next development phase of the Company's revolutionary Transrenal-DNA (Tr-DNA) technology. The study will test the technology's ability to non-invasively detect Down syndrome in unborn babies using a safe and simple urine collection from the mother. Under the research agreement, which is subject to institutional review board approval, Xenomics and North Shore-LIJ will collaborate to begin human clinical studies of the Company's safe, inexpensive and non-invasive medical tests to detect Down syndrome, a serious genetic abnormality, in unborn children. North Shore-LIJ, a 14-hospital network serving Long Island, Queens and Staten Island that treats a large population of high-risk pregnancy patients, will provide Xenomics scientists with anonymous urine samples from expectant mothers carrying children identified with Down syndrome. This will enable Xenomics to conduct the next phase of clinical studies as it develops its technology for the diagnostic marketplace.

Read at BioSpace.com

Related News

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->